The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
Open accessAbstract
Purpose: To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17- demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials. Patients and Methods: This was a phase I study examining a once-weekly dosing schedule of 17-AAG. Thirty patients with advanced malignancies were treated. Results: The highest dose level reached was 450 mg/m 2/week. The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patients (one at 320 mg/m 2/week and two at 450 mg/m 2/week) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m 2/week. Two of nine DLTs were at the highest dose level. Two patients with metastatic melanoma had stable disease and were treated for 15 and 41 months, respectively. The dose versus area under the curve-relationship for 17-AAG was linear (r 2 = .71) over the dose range 10 to 450 mg/m 2/week, with peak plasma concentrations of 8,998 μg/L (standard deviation, 2,881) at the highest dose level. After the demonstration of pharmacodynamic changes in peripheral blood leukocytes, pre- and 24 hours post-treatment, tumor biopsies were performed and demonstrated target inhibition (c-RAF-1 inhibition in four of six patients, CDK4 depletion in eight of nine patients and HSP70 induction in eight of nine patients) at the dose levels 320 and 450 mg/m 2/week. It was not possible to reproducibly demonstrate these changes in biopsies taken 5 days after treatment. Conclusion: It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with therapeutic plasma concentrations and target inhibition for 24 hours after treatment and some indications of clinical activity at the dose level 450 mg/m 2/week. We recommend this dose for phase II clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioanalytical Method Validation—A Revisit with a Decade of Progress
Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007669411738 · Cited by 1,572
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Santos, N. C., Figueira-Coelho, J., Martins-Silva, J., & Saldanha, C. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00002-9 · Cited by 648
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Self-citationPreclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J. E., Roe, S. M., Piper, P. W., & Pearl, L. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4383 · Cited by 492
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
Xu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 350
Self-citationHostein, I., Robertson, D. M., Di-Stefano, F., Workman, P., & Clarke, P. A. (2001) · PubMed · Cited by 320
Self-citationRole of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent
Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., & Rimerman, R. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6804 · Cited by 289
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Structure and Functional Relationships of Hsp90
Prodromou, C., & Pearl, L. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481877 · Cited by 261
Stable Association of hsp90 and p23, but Not hsp70, with Active Human Telomerase
Forsythe, H. L., Jarvis, J. L., Turner, J. W., Elmore, L. W., & Holt, S. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100055200 · Cited by 248
Nimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
Hsp90 Regulates Androgen Receptor Hormone Binding Affinity in Vivo
Fang, Y., Fliss, A. E., Robins, D. M., & Caplan, A. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28697 · Cited by 227
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206
Clarke, P. A., Hostein, I., Banerji, U., Stefano, F. D., Maloney, A., Walton, M., Judson, I., & Workman, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203753 · Cited by 194
Self-citationGeldanamycin-Induced Destabilization of Raf-1 Involves the Proteasome
Schulte, T. W., An, W. G., & Neckers, L. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7527 · Cited by 190
Münster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Egorin, M. J., Rosen, D. M., Wolff, J., Callery, P. S., Musser, S. M., & Eiseman, J. L. (1998) · PubMed · Cited by 133
Egorin, M. J., Zuhowski, E. G., Rosen, D. M., Sentz, D. L., Covey, J. M., & Eiseman, J. L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000242 · Cited by 133
Inhibitors of HSP90 and other chaperones for the treatment of cancer
Dymock, B. W., Drysdale, M. J., McDonald, E., & Workman, P. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.6.837 · Cited by 46
Self-citationHidalgo, M. M., Aylesworth, C. A., Hammond, L. A., Britten, C. D., Weiss, G. R., Stephenson, J., Schwartz, G. H., Patnaik, A., Smith, L. S., Molpus, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2493 · Cited by 42
Cited by
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Self-citation
Metadata
- Authors
- Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., Walton, M., Lakhani, S., Kaye, S., Workman, P., & Judson, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-20
- Volume
- 23
- Issue
- 18
- Pages
- 4152-4161
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112417555
- Cited by
- 488
- References
- 27
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.